{"paper_id": "b33997cde8b5814d29b98188de9cda073f29022f", "metadata": {"title": "Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in the pre-and post-HAART eras", "authors": [{"first": "Luis", "middle": ["E"], "last": "Vega", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Luis", "middle": ["R"], "last": "Espinoza", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [{"text": "Rheumatic manifestations remain an important clinical manifestation associated to HIV. To date after 4 decades of the onset of the HIV/AIDS pandemic, almost 37 million individuals are living with the infection, including close to 2 million of newly infected individuals. The status, however, of a considerable proportion of HIV/AIDS patients has changed from a near fatal disorder secondary to opportunistic infections to a chronic disease in which renal cardiovascular, diabetes, malignancy, and autoimmune co-morbid disorders have become prevalent and relevant. In addition, the spectrum of rheumatic disorders also has changed since the introduction of HAART and its diagnosis and treatment represents a challenge. The purpose of this review is to define and discuss the HIV-related rheumatic manifestations in the pre-and post-HAART eras.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "The past few decades have been characterized by the occurrence of several infections, some emerging and other reemerging, despite extraordinary advances in diagnostics, therapeutics, and vaccine development [1, 2] . Several factors contributing to the emergence of recent epidemics have been identified, including genetic adaptations of the microbial agent, international travel, human susceptibility to infection, population growth, an aging population, climate and weather changes, and expanding vector habitats [2] [3] [4] [5] . Four recent examples of disease emergences are the viral infections such as Chikungunya, Zika, Middle East Respiratory syndrome coronavirus (MERS-CoV), and the recently described novel coronavirus (COVID- 19) infection, which represent new viral entities or viruses emergent in new geographic locales and characterized by novel complications [6] [7] [8] . However, the most important newest example of an emergent infectious disease is HIV infection, which emerged a century ago in a primate host(s), and subsequently spread within the human population.", "cite_spans": [{"start": 207, "end": 210, "text": "[1,", "ref_id": "BIBREF0"}, {"start": 211, "end": 213, "text": "2]", "ref_id": "BIBREF1"}, {"start": 514, "end": 517, "text": "[2]", "ref_id": "BIBREF1"}, {"start": 518, "end": 521, "text": "[3]", "ref_id": "BIBREF2"}, {"start": 522, "end": 525, "text": "[4]", "ref_id": "BIBREF3"}, {"start": 526, "end": 529, "text": "[5]", "ref_id": "BIBREF4"}, {"start": 737, "end": 740, "text": "19)", "ref_id": "BIBREF18"}, {"start": 874, "end": 877, "text": "[6]", "ref_id": "BIBREF5"}, {"start": 878, "end": 881, "text": "[7]", "ref_id": "BIBREF6"}, {"start": 882, "end": 885, "text": "[8]", "ref_id": "BIBREF7"}], "ref_spans": [], "section": "Introduction"}, {"text": "Remarkable progress in our understanding of etiopathogenesis, natural course, diagnostics, and therapy (HAART) has occurred, which has led to a significant improvement in morbidity and mortality (9) . To date, the status of a considerable proportion of HIV/AIDS patients has changed from a near fatal disorder secondary to opportunistic infections to a chronic disease in which cardiovascular, renal, diabetes, malignancy, and autoimmune co-morbid disorders have become prevalent and relevant [9] [10] [11] . The latter manifestations in which HIV-related rheumatic manifestations are included, make this topic of great relevance and importance to clinicians including rheumatologists and other practitioners dealing with this condition. This review will attempt to define and discuss available data on HIV infection and rheumatic manifestations during the pre-and post-HAART eras.", "cite_spans": [{"start": 195, "end": 198, "text": "(9)", "ref_id": "BIBREF8"}, {"start": 493, "end": 496, "text": "[9]", "ref_id": "BIBREF8"}, {"start": 497, "end": 501, "text": "[10]", "ref_id": "BIBREF9"}, {"start": 502, "end": 506, "text": "[11]", "ref_id": "BIBREF10"}], "ref_spans": [], "section": "Introduction"}, {"text": "Prevalence of rheumatic manifestations before the advent of highly active antiretroviral therapy", "cite_spans": [], "ref_spans": [], "section": "Introduction"}, {"text": "The prevalence of rheumatic manifestations among HIVinfected patients prior to the introduction of HAART ranged from 3 to 71% [12] and was associated with late stages of immunosuppression in HIV infection. And HIV-associated arthritis, reactive arthritis (ReA), psoriatic arthritis (PsA), painful articular syndrome, and diffuse infiltrative lymphocytosis syndrome (DILS) were the most commonly rheumatic disorders observed. In this pre-HAART era, the coexistence of HIV infection and systemic lupus erythematosus or rheumatoid arthritis was rarely observed given that these two diseases are CD4+ T cell-mediated process and HIV targets CD4+ T cell, therefore reducing the risk of development of these rheumatic diseases. After the introduction of HAART, rheumatic complications had a significant decline, including DILS, ReA, PsA, and myositis [13] [14] [15] (see Table 1 ).", "cite_spans": [{"start": 126, "end": 130, "text": "[12]", "ref_id": "BIBREF11"}, {"start": 845, "end": 849, "text": "[13]", "ref_id": "BIBREF12"}, {"start": 850, "end": 854, "text": "[14]", "ref_id": "BIBREF13"}, {"start": 855, "end": 859, "text": "[15]", "ref_id": "BIBREF14"}], "ref_spans": [{"start": 865, "end": 872, "text": "Table 1", "ref_id": "TABREF1"}], "section": "Introduction"}, {"text": "Several prospective studies have conclusively shown that the prevalence of rheumatic manifestations associated to HIV infection has significantly declined in the HAART era, but of great interest and importance, a new group of rheumatic disorders has emerged covering the spectrum of systemic autoimmune and autoinflammatory diseases, posing a new clinical challenge [13] [14] [15] [16] [17] (see Table 2 ).", "cite_spans": [{"start": 366, "end": 370, "text": "[13]", "ref_id": "BIBREF12"}, {"start": 371, "end": 375, "text": "[14]", "ref_id": "BIBREF13"}, {"start": 376, "end": 380, "text": "[15]", "ref_id": "BIBREF14"}, {"start": 381, "end": 385, "text": "[16]", "ref_id": "BIBREF15"}, {"start": 386, "end": 390, "text": "[17]", "ref_id": "BIBREF16"}], "ref_spans": [{"start": 396, "end": 403, "text": "Table 2", "ref_id": "TABREF0"}], "section": "Prevalence of rheumatic manifestations after the advent of HAART"}, {"text": "Walker-Bone et al. recently reported their experience with 363 HIV-positive patients, out of a cohort of 2042 HIVinfected patients (1837 (90%) male), with musculoskeletal manifestations seen between January 2005 and December 2012. Most (310, 85%) patients had no evidence of an underlying systemic inflammatory disorder but were diagnosed with regional musculoskeletal pain, specific soft tissue disorders, chronic widespread pain, or osteoarthritis. Among the remaining 53, only seronegative arthritides were present more often than would be expected for the general population [18] .", "cite_spans": [{"start": 579, "end": 583, "text": "[18]", "ref_id": "BIBREF17"}], "ref_spans": [], "section": "Prevalence of rheumatic manifestations after the advent of HAART"}, {"text": "There are few studies dealing with the incidence, prevalence, and chronology between rheumatic disorders associated with HIV infection and AIDS; however, two large studies, one from Taiwan and the second from France, merit discussion [19, 20] . In the first study, Yen et al. reported on the incidence of AIDS in a nation-wide HIV/AIDS patient (PLWHA) cohort in Taiwan and compared with the general population. An interesting observation was the lower risk for development of AS despite a high prevalence of HLA-B27 in Taiwanese people (5%). In contrast, PLWHA who received HAART had higher standardized incidence rates (SIRs) for psoriasis, AHA, and uveitis, while those that did not receive HAART had higher SIRs for Sjogren's syndrome, psoriasis, RA, SLE, and other autoimmune disorders. Lebrun et al. also conducted an epidemiologic study in a French nation-wide HIV cohort to estimate the prevalence of inflammatory and autoimmune diseases (IADs) among patients living with HIV (PLHIV) in the HAART era (from January 2000 to July 2013), and to describe their occurrence according to HAART onset, the immunevirological status, and hepatitis C virus (HCV) and/or hepatitis B virus coinfection. Published reports showed that several IADs including psoriasis, sarcoidosis, RA, ankylosis spondylitis (AS), Graves' disease, Hashimoto's thyroiditis, autoimmune hemolytic anemia (AHA), immune thrombocytopenia, autoimmune hepatitis, myasthenia gravis (MG), Guillain-Barre syndrome (GBS), and chronic inflammatory bowel disease were the most prevalent diseases. Majority of patients (59%) developed IAD after HIV infection with a mean delay of 10.6 \u00b1 6.4 years. In addition, in patients developing IAD after the diagnosis of HIV infection, 572 (70%) were on HAART and 419 of them (73%) had undetectable HIV viral load. Comparing data from the Taiwan and French studies, some geographical variability in terms of IADs is observed but both studies confirmed previous reports in the literature concerning the relationship between HIV/AIDS and rheumatic disorders.", "cite_spans": [{"start": 234, "end": 238, "text": "[19,", "ref_id": "BIBREF18"}, {"start": 239, "end": 242, "text": "20]", "ref_id": "BIBREF19"}], "ref_spans": [], "section": "Prevalence of rheumatic manifestations after the advent of HAART"}, {"text": "Most reports in the pre-HAART era clearly demonstrated a worldwide increase in the prevalence of ReA, PsA, and to a lesser extent AS compared with the general population, although some differences were noted according to mode of transmission, geographic variation, and degree of immunosuppression. This was more striking for both psoriasis and PsA in sub-Saharan African countries in which the incidence and prevalence of both disorders were low despite the presence of the risk allele for psoriasis HLA-CW6. This, however, drastically changed following the advent of HIV in which both disorders were increasingly seen in African populations [12, [21] [22] [23] [24] . A similar situation occurred in Asian populations in which both psoriasis and PsA were of low prevalence, only to increase following the HIV pandemic. Post-HAART, both psoriasis and PsA have diminished in Africa and Asia.", "cite_spans": [{"start": 642, "end": 646, "text": "[12,", "ref_id": "BIBREF11"}, {"start": 647, "end": 651, "text": "[21]", "ref_id": "BIBREF20"}, {"start": 652, "end": 656, "text": "[22]", "ref_id": "BIBREF21"}, {"start": 657, "end": 661, "text": "[23]", "ref_id": "BIBREF22"}, {"start": 662, "end": 666, "text": "[24]", "ref_id": "BIBREF23"}], "ref_spans": [], "section": "Spondyloarthritis"}, {"text": "Early reports showed that patients with active rheumatoid arthritis (RA) became inactive following infection with VIH; however, this situation did not occur in all RA patients and erosive RA has been shown to develop even in RA patients who develop AIDS. Therefore, the assertion that AIDS might lead to remission in RA requires further investigation [25, 26] .", "cite_spans": [{"start": 351, "end": 355, "text": "[25,", "ref_id": "BIBREF24"}, {"start": 356, "end": 359, "text": "26]", "ref_id": "BIBREF25"}], "ref_spans": [], "section": "Rheumatoid arthritis"}, {"text": "On the other hand, the presence of low titer rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) in patients with HIV may lead to an erroneous diagnosis of RA. HIV patients may also exhibit a high proportion of RF and CCP antibodies, which decrease after initiation of HAART suggesting that HIV is capable of inducing autoantibodies [27, 28] .", "cite_spans": [{"start": 364, "end": 368, "text": "[27,", "ref_id": "BIBREF26"}, {"start": 369, "end": 372, "text": "28]", "ref_id": null}], "ref_spans": [], "section": "Rheumatoid arthritis"}, {"text": "Overlapping clinical and laboratory presentations of SLE and HIV infection may give rise to diagnostic challenges; active SLE and HIV infection shared several manifestations such as fever, arthralgia, arthritis, myalgia, skin rash, lymph node enlargement, cytopenias, pulmonary, cardiovascular, renal and CNS involvement, ANAs, and anticardiolipin antibodies, but hypocomplementemia secondary to HIV has not been described, and this finding may be useful to distinguish lupus activity from HIV infection [29] .", "cite_spans": [{"start": 504, "end": 508, "text": "[29]", "ref_id": null}], "ref_spans": [], "section": "Systemic lupus erythematosus"}, {"text": "Decrease in CD4 lymphocytes might ameliorate SLE disease activity and induce remission. However, it is interesting to note that SLE disease activity may persist during HIV infection and not be related to the use of HAART demonstrating that CD4+ cells are not the only player in this immunodeficiency disease [30] .", "cite_spans": [{"start": 308, "end": 312, "text": "[30]", "ref_id": null}], "ref_spans": [], "section": "Systemic lupus erythematosus"}, {"text": "Two recently published reports highlight the association between HIV infection and SLE. Hax et al. described 11 patients exhibiting concomitant HIV and SLE in whom the most salient features were more neuropsychiatric lupus and smoking, and higher SLICC damage index as compared with SLE patients without HIV infection, although the survival rate was similar in both groups. In addition, anti-Sm antibody was found more prevalent in patients with SLE without HIV [31]. ", "cite_spans": [], "ref_spans": [], "section": "Systemic lupus erythematosus"}, {"text": "Circulating antiphospholipid antibodies, including anticardiolipin, lupus anticoagulant, and anti-B2-glycoprotein I, are a common occurrence in most HIV patients, but in general, their clinical significance is irrelevant. Only a handful of clinical cases have been reported [12, 31, 32 ].", "cite_spans": [{"start": 274, "end": 278, "text": "[12,", "ref_id": "BIBREF11"}, {"start": 279, "end": 282, "text": "31,", "ref_id": null}, {"start": 283, "end": 285, "text": "32", "ref_id": null}], "ref_spans": [], "section": "Anti-phospholipid syndrome"}, {"text": "The association between HIV infection and systemic sclerosis (SSc) is rare. The few cases reported in the literature do not allow for a meaningful analysis [33, 34].", "cite_spans": [], "ref_spans": [], "section": "Systemic sclerosis"}, {"text": "HIV-associated polymyositis usually has mild disease activity, which is often difficult to recognize, especially in a population that frequently presents generalized weakness and a debilitating course. Other causes of myopathy reported are high dose of zidovudine, statins-related, and nemaline myopathy [35].", "cite_spans": [], "ref_spans": [], "section": "Polymyositis and dermatomyositis"}, {"text": "Prior to HAART its prevalence used to be highest among African Americans (up to 48% of infected individuals) and associated with HLA class II alleles (DRB1) that is not seen in other racial groups with diffuse infiltrative lymphocytosis syndrome (DILS), and occurring in patients whose disease was at a less advanced stages. The syndrome usually presents as a Sjogren-like disease with sicca symptoms with bilateral parotid gland swelling, lymphadenopathy, and extra-glandular organ involvement. DILS is also characterized by CD8+ T cell infiltration, lack of autoantibodies (anti-Ro and anti-La), although they may be present in some exceptions, and extraglandular visceral infiltration. The lung being the most common extra-glandular organ involved and when affected it presents as a lymphocytic interstitial pneumonitis (LIP) [36] . Its natural history has also changed since the introduction of HAART, and it is less frequently seen including the extraglandular manifestations such as LIP.", "cite_spans": [{"start": 829, "end": 833, "text": "[36]", "ref_id": null}], "ref_spans": [], "section": "Diffuse infiltrative lymphocytosis syndrome"}, {"text": "Chen et al. showed in the Taiwanese population that the incident rate of DILS was 0.56/1000 person-years higher than in the general population, and the incidence was higher in patients without HAART than in patients with HAART, supporting the notion that HIV intervenes in the pathogenesis of DILS and that HAART reduces the risk of acquiring DILS [15, 19] .", "cite_spans": [{"start": 348, "end": 352, "text": "[15,", "ref_id": "BIBREF14"}, {"start": 353, "end": 356, "text": "19]", "ref_id": "BIBREF18"}], "ref_spans": [], "section": "Diffuse infiltrative lymphocytosis syndrome"}, {"text": "DILS patients with mild symptoms may not require specific treatment, but glucocorticoids or immunosuppressive drugs should be considered for patients with progressive glandular involvement.", "cite_spans": [], "ref_spans": [], "section": "Diffuse infiltrative lymphocytosis syndrome"}, {"text": "The incidence of vasculitis in HIV infection is relatively low 1%, and when present it can affect small, medium, and large size blood vessels. Its presence, however, varies according to ethnic origin, and it appears to have a higher prevalence in Orientals, and on the route of transmission. Vasculitis occurs more commonly in those with a profound state of immunosuppression (CD4+ < 200/mL), in association with hepatitis B infection, but has also been reported in the early stages (> 500/ mL) [ ", "cite_spans": [{"start": 495, "end": 496, "text": "[", "ref_id": null}], "ref_spans": [], "section": "Vasculitis"}, {"text": "Contrary to what might be expected, osteoarticular infection due to pyogenic bacterial does not occur more frequently in patients with HIV infection, and published data reveals a relatively low risk for septic arthritis [13, 47] . However, it should be noted that there is a single study that reported a prevalence of infection of 20% [22] . Atypical microorganisms rarely occur except in advanced HIV infection. Atypical mycobacterium and fungal microorganisms occur in advanced HIV infection (CD4 count less than 100/mL).", "cite_spans": [{"start": 220, "end": 224, "text": "[13,", "ref_id": "BIBREF12"}, {"start": 225, "end": 228, "text": "47]", "ref_id": "BIBREF27"}, {"start": 335, "end": 339, "text": "[22]", "ref_id": "BIBREF21"}], "ref_spans": [], "section": "Septic arthritis"}, {"text": "Restoration of immune competence associated to suppression of virologic response following initiation of HAART might result in development of autoimmune disorders and reactivation of underlying opportunistic infections. This constellation of events known as immune reconstitution inflammatory syndrome (IRIS) is linked to a rapidly recovering immune system, and it appears directly related to an increase in CD4+ T cells, CD8+ T cells, CD4+:CD8+ T cell ratio, and increased cytokine levels.", "cite_spans": [], "ref_spans": [], "section": "Immune reconstitution inflammatory syndrome"}, {"text": "Calabrese et al. conducted a prospective, longitudinal cohort study and described 32 cases associated with IRIS including sarcoidosis, RA, and SLE [14] .", "cite_spans": [{"start": 147, "end": 151, "text": "[14]", "ref_id": "BIBREF13"}], "ref_spans": [], "section": "Immune reconstitution inflammatory syndrome"}, {"text": "IRIS may develop days to months after HAART begins, and most cases resolve spontaneously, but at times they can become life-threatening in severity, requiring therapeutic interventions. Generally, however, IRIS is a self-limiting process in which it is not necessary to discontinue HAART, and it should not require lifelong therapy [14, 48] .", "cite_spans": [{"start": 332, "end": 336, "text": "[14,", "ref_id": "BIBREF13"}, {"start": 337, "end": 340, "text": "48]", "ref_id": "BIBREF28"}], "ref_spans": [], "section": "Immune reconstitution inflammatory syndrome"}, {"text": "Bone diseases (see Table 3 )", "cite_spans": [], "ref_spans": [{"start": 19, "end": 26, "text": "Table 3", "ref_id": "TABREF3"}], "section": "Immune reconstitution inflammatory syndrome"}, {"text": "As longevity in HIV-infected individuals increases, new comorbid conditions including osteopenia and osteoporosis, with their increase in the risk of bone fractures, develop. The estimated prevalence of osteoporosis in the HIV population is 15% and of osteopenia 52%. Bone density decreases between 2 and 6% during the first 2 years of HAART [49, 50] , and the rate of fracture in the HIV population is between 30 and 70% compared with control non-HIV population [51] [52] [53] .", "cite_spans": [{"start": 342, "end": 346, "text": "[49,", "ref_id": "BIBREF29"}, {"start": 347, "end": 350, "text": "50]", "ref_id": "BIBREF30"}, {"start": 463, "end": 467, "text": "[51]", "ref_id": "BIBREF31"}, {"start": 468, "end": 472, "text": "[52]", "ref_id": "BIBREF32"}, {"start": 473, "end": 477, "text": "[53]", "ref_id": "BIBREF33"}], "ref_spans": [], "section": "Osteoporosis"}, {"text": "In addition, to classic osteoporosis risk factors other HIVspecific risk factors such as low CD4+ cell count, coinfection with hepatitis C, and antiretroviral therapy may all contribute to the increase risk in osteoporosis [51, 52] .", "cite_spans": [{"start": 223, "end": 227, "text": "[51,", "ref_id": "BIBREF31"}, {"start": 228, "end": 231, "text": "52]", "ref_id": "BIBREF32"}], "ref_spans": [], "section": "Osteoporosis"}, {"text": "There is no specific guide for the assessment and management of HIV patients with decreased bone density; however, FRAX has been recommended for routine evaluation of fracture risk in PLWH despite the limited predictive value in these patients [54] .", "cite_spans": [{"start": 244, "end": 248, "text": "[54]", "ref_id": "BIBREF34"}], "ref_spans": [], "section": "Osteoporosis"}, {"text": "Management of osteoporosis in PLWH should follow the same recommendations for the HIV-negative population, an adequate nutrition including calcium and vitamin D and modification of lifestyles, pharmacological therapy with bisphosphonates, alendronate and zoledronic acid, have been shown to have a positive effect on BMD and tolerability similar to those found in the general population [54] [55] [56] [57] . Currently, other therapeutic options have not been evaluated.", "cite_spans": [{"start": 387, "end": 391, "text": "[54]", "ref_id": "BIBREF34"}, {"start": 392, "end": 396, "text": "[55]", "ref_id": "BIBREF35"}, {"start": 397, "end": 401, "text": "[56]", "ref_id": "BIBREF36"}, {"start": 402, "end": 406, "text": "[57]", "ref_id": "BIBREF37"}], "ref_spans": [], "section": "Osteoporosis"}, {"text": "Osteonecrosis (avascular bone necrosis, AVN) may occur at any joint, but when affects hips or any other large joint might eventually lead to severe disability. AVN might have a higher incidence than in the general population [58] . Its prevalence might be comparable to the prevalence reported in patients at high risk for osteonecrosis in the context of a variety of underlying diseases, i.e., glucocorticoid-induced AVN.", "cite_spans": [{"start": 225, "end": 229, "text": "[58]", "ref_id": "BIBREF38"}], "ref_spans": [], "section": "Avascular bone necrosis"}, {"text": "Its etiology and potential risk factors are poorly understood, and further studies are needed to have a better understanding of this complication [59] .", "cite_spans": [{"start": 146, "end": 150, "text": "[59]", "ref_id": "BIBREF39"}], "ref_spans": [], "section": "Avascular bone necrosis"}, {"text": "HIV infection has significantly impacted on the natural history and therapeutic intervention of autoimmune diseases due to the presence of underlying immunosuppression and that the use of immunosuppressive drugs or biologic agents may lead to serious complications including infections.", "cite_spans": [], "ref_spans": [], "section": "Therapy of rheumatic disorders in HIV-infected patients"}, {"text": "Management of autoimmune diseases (AIDs) is similar in HIV-positive and HIV-negative patients. Most patients afflicted with HIV-associated AIDs including inflammatory musculoskeletal involvement respond well to conventional therapy such as NSAIDs, narcotic drugs, and DMARDs, but refractory cases may need the use of biological agents, especially TNF inhibitors [60] . When considering immune suppressive therapy, it is important to keep in mind that CD4+ T cells are necessary in the control of intracellular and extracellular bacteria, parasites, and viruses [61] .", "cite_spans": [{"start": 362, "end": 366, "text": "[60]", "ref_id": "BIBREF40"}, {"start": 561, "end": 565, "text": "[61]", "ref_id": "BIBREF41"}], "ref_spans": [], "section": "Therapy of rheumatic disorders in HIV-infected patients"}, {"text": "At present, biologic agents and other DMARDs (including glucocorticoids, hydroxychloroquine, sulfasalazine, methotrexate, leflunomide, mofetil mycophenolate, azathioprine, cyclophosphamide, cyclosporine) are recommended when patients have CD4+ T cell counts above 200 cells/mm 3 and HIV viral activity completely suppressed [62] [63] [64] . In addition, they have been shown to be effective, safe, and well-tolerated. In certain situations, especially in lupus patients, treatment should be individualized and should be tailored at reaching a balance between HIV infection and lupus activity.", "cite_spans": [{"start": 324, "end": 328, "text": "[62]", "ref_id": "BIBREF42"}, {"start": 329, "end": 333, "text": "[63]", "ref_id": "BIBREF43"}, {"start": 334, "end": 338, "text": "[64]", "ref_id": "BIBREF44"}], "ref_spans": [], "section": "Therapy of rheumatic disorders in HIV-infected patients"}, {"text": "General consensus suggests that prophylaxis against opportunistic infection should be given to all HIV patients on immunosuppressive therapy due to an increased risk of infection reactivation. Special attention should be given to the presence of tuberculosis (TB), varicella zozter, and opportunistic infections such as Pneumocystis jirovecci (PJ) [62, 65] . In addition, HIV patients should be screened for HBV, HVC, and other infections taking into considerations endemic geography [66] . Prophylaxis for TB should follow the CDC guidelines, although no guidelines for the prophylaxis of PJ in connective tissue disorders exist [67] [68] [69] .", "cite_spans": [{"start": 348, "end": 352, "text": "[62,", "ref_id": "BIBREF42"}, {"start": 353, "end": 356, "text": "65]", "ref_id": "BIBREF45"}, {"start": 484, "end": 488, "text": "[66]", "ref_id": "BIBREF46"}, {"start": 630, "end": 634, "text": "[67]", "ref_id": "BIBREF47"}, {"start": 635, "end": 639, "text": "[68]", "ref_id": "BIBREF48"}, {"start": 640, "end": 644, "text": "[69]", "ref_id": "BIBREF49"}], "ref_spans": [], "section": "Prophylaxis"}, {"text": "HIV patients on immunosuppressive therapy have an increased risk of infection reactivation. Close attention to the association between tuberculosis, varicella zoster, and opportunistic infections such as PJ should be kept in mind [62, 65] . Patients should be screened for HIV viral load, HBV, HVC, TB, and other infections according to endemic geography [66] .", "cite_spans": [{"start": 230, "end": 234, "text": "[62,", "ref_id": "BIBREF42"}, {"start": 235, "end": 238, "text": "65]", "ref_id": "BIBREF45"}, {"start": 355, "end": 359, "text": "[66]", "ref_id": "BIBREF46"}], "ref_spans": [], "section": "Prophylaxis"}, {"text": "It can be concluded that following the introduction of HAART, there has been a decline in the incidence and prevalence of seronegative arthritides and certain autoimmune disorders including DILS, SLE, RA, and polymyositis, but certain systemic metabolic and inflammatory disorders, especially osteoporosis, avascular bone necrosis, immune reconstitution syndrome, sarcoidosis, autoimmune hemolytic anemia, Graves' disease, psoriasis, immune thrombocytopenia, and inflammatory bowel disease have emerged. Glucocorticoids and other immunosuppressive agents appear to be effective and well-tolerated, and prophylaxis of infection is very important.", "cite_spans": [], "ref_spans": [], "section": "Conclusion"}, {"text": "Disclosures None. ", "cite_spans": [], "ref_spans": [], "section": "Compliance with ethical standards"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Emerging infections: a perpetual challenge", "authors": [{"first": "D", "middle": ["M"], "last": "Morens", "suffix": ""}, {"first": "G", "middle": ["K"], "last": "Folkers", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Fauci", "suffix": ""}], "year": 2008, "venue": "Lancet Infect Dis", "volume": "8", "issn": "", "pages": "710--719", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Emerging infectious diseases: threats to human health and global stability", "authors": [{"first": "D", "middle": ["M"], "last": "Morens", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Fauci", "suffix": ""}], "year": 2013, "venue": "PLoS Pathog", "volume": "9", "issn": "", "pages": "", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "Emerging infectious disease risk: shared drivers with environmental change", "authors": [{"first": "C", "middle": ["M"], "last": "Machalaba", "suffix": ""}, {"first": "W", "middle": ["B"], "last": "Karesh", "suffix": ""}], "year": 2017, "venue": "Rev Sci Tech", "volume": "36", "issn": "", "pages": "435--444", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Evolutionary emergence of infectious diseases in heterogeneous host populations", "authors": [{"first": "H", "middle": [], "last": "Chabas", "suffix": ""}, {"first": "S", "middle": [], "last": "Lion", "suffix": ""}, {"first": "A", "middle": [], "last": "Nicot", "suffix": ""}], "year": 2018, "venue": "PLoS Biol", "volume": "24", "issn": "", "pages": "", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Genome characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans", "authors": [{"first": "S", "middle": [], "last": "Van Boheemen", "suffix": ""}, {"first": "M", "middle": [], "last": "De Graaf", "suffix": ""}, {"first": "C", "middle": [], "last": "Lauber", "suffix": ""}], "year": 2012, "venue": "MBio", "volume": "3", "issn": "", "pages": "473--00412", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "The challenges imposed by dengue, zika, and chikungunya to Brazil", "authors": [{"first": "Pma", "middle": [], "last": "Zanotto", "suffix": ""}, {"first": "Lcc", "middle": [], "last": "Leite", "suffix": ""}], "year": 2018, "venue": "Front Immunol", "volume": "9", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fimmu.2018.01964"]}}, "BIBREF6": {"ref_id": "b6", "title": "UNAIDS. Fact sheet-latest statistics on the status of the AIDS epidemic 2016", "authors": [], "year": 2017, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {"DOI": ["10.3389/fimmu.2018.01964"]}}, "BIBREF7": {"ref_id": "b7", "title": "Severe acute respiratory disease coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019", "authors": [{"first": "C", "middle": ["C"], "last": "Lai", "suffix": ""}, {"first": "T", "middle": ["P"], "last": "Shih", "suffix": ""}, {"first": "W", "middle": ["C"], "last": "Ko", "suffix": ""}, {"first": "H", "middle": ["J"], "last": "Tang", "suffix": ""}, {"first": "P", "middle": ["R"], "last": "Hsueh", "suffix": ""}], "year": 2020, "venue": "Int J Antimicrob Agents", "volume": "105924", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1016/j.ijantimicag.2020.105924"]}}, "BIBREF8": {"ref_id": "b8", "title": "HIV infection and its effects on the development of autoimmune disorders", "authors": [{"first": "L", "middle": ["E"], "last": "Vega", "suffix": ""}, {"first": "L", "middle": ["R"], "last": "Espinoza", "suffix": ""}], "year": 2018, "venue": "Pharmacol Res", "volume": "129", "issn": "", "pages": "1--9", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "Ageing with HIV: do comorbidities and polymedication drive treatment optimization", "authors": [{"first": "L", "middle": [], "last": "Cuzin", "suffix": ""}, {"first": "C", "middle": [], "last": "Katlama", "suffix": ""}, {"first": "L", "middle": [], "last": "Cotte", "suffix": ""}], "year": 2016, "venue": "HIV Med", "volume": "", "issn": "", "pages": "1--7", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "Autoimmune diseases in HIV-infected patients: 52 cases and literature review", "authors": [{"first": "L", "middle": [], "last": "Iordache", "suffix": ""}, {"first": "O", "middle": [], "last": "Launay", "suffix": ""}, {"first": "O", "middle": [], "last": "Bouchaud", "suffix": ""}, {"first": "V", "middle": [], "last": "Jeantils", "suffix": ""}], "year": 2014, "venue": "Autoimmun Rev", "volume": "13", "issn": "", "pages": "850--857", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Evolving spectrum of HIV-associated rheumatic syndromes", "authors": [{"first": "C", "middle": [], "last": "Fox", "suffix": ""}, {"first": "K", "middle": [], "last": "Walke-Bone", "suffix": ""}], "year": 2015, "venue": "Best Pract Res Clin Rheumatol", "volume": "29", "issn": "", "pages": "244--258", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era", "authors": [{"first": "B", "middle": ["Y"], "last": "Nguyen", "suffix": ""}, {"first": "J", "middle": ["D"], "last": "Reveille", "suffix": ""}], "year": 2009, "venue": "Curr Opin Rheumatol", "volume": "21", "issn": "", "pages": "404--410", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease", "authors": [{"first": "L", "middle": [], "last": "Calabrese", "suffix": ""}, {"first": "E", "middle": [], "last": "Kirchner", "suffix": ""}, {"first": "R", "middle": [], "last": "Shrestha", "suffix": ""}], "year": 2005, "venue": "Semin Arthritis Rheum", "volume": "35", "issn": "", "pages": "166--174", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Risk of diffuse infiltrative lymphocytosis syndrome in HIV-infected patients: a nationwide population-based cohort study", "authors": [{"first": "M", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Y", "middle": ["F"], "last": "Yen", "suffix": ""}, {"first": "Y", "middle": ["C"], "last": "Lan", "suffix": ""}, {"first": "I", "middle": ["A"], "last": "Jen", "suffix": ""}, {"first": "P", "middle": ["H"], "last": "Chuang", "suffix": ""}, {"first": "C", "middle": ["Y"], "last": "Lee", "suffix": ""}, {"first": "Y", "middle": [], "last": "Lee", "suffix": ""}, {"first": "Y", "middle": ["A"], "last": "Lin", "suffix": ""}], "year": 2018, "venue": "J Acquir Immune Defic Syndr", "volume": "79", "issn": "", "pages": "158--163", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "Rheumatic diseases in HIV-infected patients in the postantiretroviral therapy era: a tertiary care center experience", "authors": [{"first": "K", "middle": [], "last": "Parperis", "suffix": ""}, {"first": "Y", "middle": [], "last": "Abdulqader", "suffix": ""}, {"first": "R", "middle": [], "last": "Myers", "suffix": ""}, {"first": "B", "middle": [], "last": "Bhattarai", "suffix": ""}, {"first": "Al-Ani", "middle": [], "last": "", "suffix": ""}, {"first": "M", "middle": [], "last": "", "suffix": ""}], "year": 2019, "venue": "Clin Rheumatol", "volume": "38", "issn": "", "pages": "71--76", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "Autoimmune diseases-related arthritis in HIVinfected patients in the era of higly active antiretroviral therapy", "authors": [{"first": "J", "middle": ["J"], "last": "Yang", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Tsai", "suffix": ""}, {"first": "H", "middle": ["Y"], "last": "Sun", "suffix": ""}, {"first": "S", "middle": ["M"], "last": "Hsieh", "suffix": ""}, {"first": "M", "middle": ["Y"], "last": "Chen", "suffix": ""}, {"first": "W", "middle": ["H"], "last": "Sheng", "suffix": ""}, {"first": "S", "middle": ["C"], "last": "Chang", "suffix": ""}], "year": 2015, "venue": "J Microbiol Immunol Infect", "volume": "48", "issn": "", "pages": "130--136", "other_ids": {}}, "BIBREF17": {"ref_id": "b17", "title": "Assessment and management of musculoskeletal disorders among patients living with HIV", "authors": [{"first": "K", "middle": [], "last": "Walker-Bone", "suffix": ""}, {"first": "E", "middle": [], "last": "Doherty", "suffix": ""}, {"first": "K", "middle": [], "last": "Sanyal", "suffix": ""}, {"first": "D", "middle": [], "last": "Churchill", "suffix": ""}], "year": 2017, "venue": "Rheumatology", "volume": "56", "issn": "", "pages": "1648--1661", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "Incidence of autoimmune diseases in a nationwide HIV/AIDS patient cohort in Taiwan", "authors": [{"first": "Y-F", "middle": [], "last": "Yen", "suffix": ""}, {"first": "P-H", "middle": [], "last": "Chuang", "suffix": ""}, {"first": "Jen I-A", "middle": [], "last": "Chen", "suffix": ""}, {"first": "M", "middle": [], "last": "", "suffix": ""}], "year": 2000, "venue": "Ann Rheum Dis", "volume": "76", "issn": "", "pages": "661--665", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "AIDS study group (2017) Epidemiology of autoimmune and inflammatory diseases in a French Nationwide HIV cohort", "authors": [{"first": "D", "middle": [], "last": "Lebrun", "suffix": ""}, {"first": "M", "middle": [], "last": "Hentzien", "suffix": ""}, {"first": "L", "middle": [], "last": "Cuzin", "suffix": ""}, {"first": "D", "middle": [], "last": "Rey", "suffix": ""}, {"first": "V", "middle": [], "last": "Joly", "suffix": ""}, {"first": "L", "middle": [], "last": "Cotte", "suffix": ""}, {"first": "C", "middle": [], "last": "Allavena", "suffix": ""}, {"first": "P", "middle": [], "last": "Dellamonica", "suffix": ""}, {"first": "A", "middle": [], "last": "Servettaz", "suffix": ""}, {"first": "F", "middle": [], "last": "Bani-Sadr", "suffix": ""}, {"first": "", "middle": [], "last": "Dat", "suffix": ""}], "year": null, "venue": "AIDS", "volume": "31", "issn": "", "pages": "2159--2166", "other_ids": {}}, "BIBREF20": {"ref_id": "b20", "title": "Autoimmune diseases and HIV infection. A cross sectional study", "authors": [{"first": "E", "middle": [], "last": "Virot", "suffix": ""}, {"first": "A", "middle": [], "last": "Duclos", "suffix": ""}, {"first": "L", "middle": [], "last": "Adelaide", "suffix": ""}, {"first": "P", "middle": [], "last": "Miailhes", "suffix": ""}, {"first": "A", "middle": [], "last": "Hot", "suffix": ""}, {"first": "T", "middle": [], "last": "Ferry", "suffix": ""}, {"first": "P", "middle": [], "last": "Seve", "suffix": ""}], "year": 2017, "venue": "Medicine", "volume": "96", "issn": "", "pages": "", "other_ids": {"DOI": ["10.1097/MD.000000000005769"]}}, "BIBREF21": {"ref_id": "b21", "title": "HIV-associated rheumatic manifestations. In: Espinoza LR (ed) Infections and the Rheumatic Diseases", "authors": [{"first": "L", "middle": ["E"], "last": "Vega", "suffix": ""}, {"first": "L", "middle": ["R"], "last": "Espinoza", "suffix": ""}], "year": 2019, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "HIVassociated psoriasis: pathogenesis, clinical features, and management", "authors": [{"first": "N", "middle": [], "last": "Morar", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Willis-Owen", "suffix": ""}, {"first": "T", "middle": [], "last": "Maurer", "suffix": ""}, {"first": "C", "middle": ["B"], "last": "Bunker", "suffix": ""}], "year": 2010, "venue": "Lancet Infect Dis", "volume": "10", "issn": "", "pages": "470--478", "other_ids": {}}, "BIBREF23": {"ref_id": "b23", "title": "Psoriatic arthritis in sub-Saharan Africa", "authors": [{"first": "D", "middle": ["D"], "last": "Ou\u00e9draogo", "suffix": ""}, {"first": "O", "middle": [], "last": "Meyer", "suffix": ""}], "year": 2012, "venue": "Joint Bone Spine", "volume": "79", "issn": "", "pages": "17--19", "other_ids": {}}, "BIBREF24": {"ref_id": "b24", "title": "HIV/AIDS and rheumatoid arthritis", "authors": [{"first": "B", "middle": ["M"], "last": "Cunha", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Mota", "suffix": ""}, {"first": "G", "middle": ["S"], "last": "Pileggi", "suffix": ""}, {"first": "I", "middle": ["P"], "last": "Safe", "suffix": ""}, {"first": "M", "middle": ["V"], "last": "Lacerda", "suffix": ""}], "year": 2015, "venue": "Autoimmun Rev", "volume": "14", "issn": "", "pages": "396--400", "other_ids": {}}, "BIBREF25": {"ref_id": "b25", "title": "Effect of human immunodeficiency virus infection on disease activity in rheumatoid arthritis: a retrospective study in south Africans", "authors": [{"first": "G", "middle": [], "last": "Tarr", "suffix": ""}, {"first": "M", "middle": [], "last": "Makda", "suffix": ""}, {"first": "E", "middle": [], "last": "Musenge", "suffix": ""}, {"first": "M", "middle": [], "last": "Tikly", "suffix": ""}], "year": 2014, "venue": "J Rheumatol", "volume": "41", "issn": "", "pages": "1645--1649", "other_ids": {}}, "BIBREF26": {"ref_id": "b26", "title": "Lack of specificity of anticyclic citrullinated peptide antibodies in advanced human immunodeficiency virus infection", "authors": [{"first": "R", "middle": [], "last": "Du Toit", "suffix": ""}, {"first": "D", "middle": [], "last": "Whitelaw", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Taljaard", "suffix": ""}, {"first": "L", "middle": [], "last": "Du Plessis", "suffix": ""}, {"first": "M", "middle": [], "last": "Esser", "suffix": ""}], "year": 2011, "venue": "J Rheumatol", "volume": "38", "issn": "", "pages": "1055--1060", "other_ids": {}}, "BIBREF27": {"ref_id": "b27", "title": "Rheumatic manifestations in HIV-1 infected in-patients and literature review", "authors": [{"first": "Q", "middle": [], "last": "Yao", "suffix": ""}, {"first": "M", "middle": [], "last": "Frank", "suffix": ""}, {"first": "M", "middle": [], "last": "Glynn", "suffix": ""}, {"first": "R", "middle": ["D"], "last": "Altman", "suffix": ""}], "year": 2008, "venue": "Clin Exp Rheumatol", "volume": "26", "issn": "", "pages": "799--780", "other_ids": {}}, "BIBREF28": {"ref_id": "b28", "title": "Immune reconstitution inflammatory syndrome in HIV-infected patients", "authors": [{"first": "N", "middle": ["F"], "last": "Walker", "suffix": ""}, {"first": "J", "middle": [], "last": "Scriven", "suffix": ""}, {"first": "G", "middle": [], "last": "Meintjes", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Wilkinson", "suffix": ""}], "year": 2015, "venue": "HIV AIDS (Auckl)", "volume": "7", "issn": "", "pages": "49--64", "other_ids": {}}, "BIBREF29": {"ref_id": "b29", "title": "Bone disease in HIV infection: a practical review and recommendations for HIV care providers", "authors": [{"first": "G", "middle": ["A"], "last": "Mccomsey", "suffix": ""}, {"first": "P", "middle": [], "last": "Tebas", "suffix": ""}, {"first": "E", "middle": [], "last": "Shane", "suffix": ""}, {"first": "M", "middle": ["T"], "last": "Yin", "suffix": ""}, {"first": "E", "middle": ["T"], "last": "Overton", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Huang", "suffix": ""}, {"first": "G", "middle": ["M"], "last": "Aldrovandi", "suffix": ""}, {"first": "S", "middle": ["W"], "last": "Cardoso", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Santana", "suffix": ""}, {"first": "T", "middle": ["T"], "last": "Brown", "suffix": ""}], "year": 2010, "venue": "Clin Infect Dis", "volume": "51", "issn": "", "pages": "937--946", "other_ids": {}}, "BIBREF30": {"ref_id": "b30", "title": "Increasing clarity on bone loss associated with antiretroviral initiation", "authors": [{"first": "M", "middle": ["T"], "last": "Yin", "suffix": ""}, {"first": "E", "middle": ["T"], "last": "Overton", "suffix": ""}], "year": 2011, "venue": "J Infect Dis", "volume": "203", "issn": "12", "pages": "1705--1707", "other_ids": {}}, "BIBREF31": {"ref_id": "b31", "title": "Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study", "authors": [{"first": "M", "middle": ["T"], "last": "Yin", "suffix": ""}, {"first": "Q", "middle": [], "last": "Shi", "suffix": ""}, {"first": "D", "middle": ["R"], "last": "Hoover", "suffix": ""}, {"first": "K", "middle": [], "last": "Anastos", "suffix": ""}, {"first": "A", "middle": [], "last": "Sharma", "suffix": ""}, {"first": "M", "middle": [], "last": "Young", "suffix": ""}, {"first": "A", "middle": [], "last": "Levine", "suffix": ""}, {"first": "M", "middle": ["H"], "last": "Cohen", "suffix": ""}, {"first": "E", "middle": [], "last": "Shane", "suffix": ""}, {"first": "E", "middle": ["T"], "last": "Golub", "suffix": ""}, {"first": "P", "middle": ["C"], "last": "Tien", "suffix": ""}], "year": 2010, "venue": "AIDS", "volume": "24", "issn": "", "pages": "2679--2686", "other_ids": {}}, "BIBREF32": {"ref_id": "b32", "title": "Low CD4 count is associated with an increased risk of fragility fracture in HIVinfected patients", "authors": [{"first": "M", "middle": ["K"], "last": "Yong", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Elliott", "suffix": ""}, {"first": "I", "middle": ["J"], "last": "Woolley", "suffix": ""}, {"first": "J", "middle": ["F"], "last": "Hoy", "suffix": ""}], "year": 2011, "venue": "J Acquir Immune Defic Syndr", "volume": "57", "issn": "", "pages": "205--210", "other_ids": {}}, "BIBREF33": {"ref_id": "b33", "title": "Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults", "authors": [{"first": "F", "middle": [], "last": "Collin", "suffix": ""}, {"first": "X", "middle": [], "last": "Duval", "suffix": ""}, {"first": "Le", "middle": [], "last": "Moing", "suffix": ""}, {"first": "V", "middle": [], "last": "", "suffix": ""}], "year": 2009, "venue": "AIDS", "volume": "23", "issn": "", "pages": "1021--1024", "other_ids": {}}, "BIBREF34": {"ref_id": "b34", "title": "Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis", "authors": [{"first": "E", "middle": [], "last": "Biver", "suffix": ""}, {"first": "A", "middle": [], "last": "Calmy", "suffix": ""}, {"first": "B", "middle": [], "last": "Aubry-Rozier", "suffix": ""}, {"first": "M", "middle": [], "last": "Birkh\u00e4user", "suffix": ""}, {"first": "H", "middle": ["A"], "last": "Bischoff-Ferrari", "suffix": ""}, {"first": "S", "middle": [], "last": "Ferrari", "suffix": ""}, {"first": "D", "middle": [], "last": "Frey", "suffix": ""}, {"first": "R", "middle": ["W"], "last": "Kressig", "suffix": ""}, {"first": "O", "middle": [], "last": "Lamy", "suffix": ""}, {"first": "K", "middle": [], "last": "Lippuner", "suffix": ""}, {"first": "N", "middle": [], "last": "Suhm", "suffix": ""}, {"first": "C", "middle": [], "last": "Meier", "suffix": ""}], "year": 2019, "venue": "Osteoporos Int", "volume": "30", "issn": "", "pages": "1125--1135", "other_ids": {}}, "BIBREF35": {"ref_id": "b35", "title": "Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV", "authors": [{"first": "G", "middle": ["A"], "last": "Mcconse", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Kendall", "suffix": ""}, {"first": "P", "middle": [], "last": "Tebas", "suffix": ""}], "year": 2007, "venue": "AIDS", "volume": "21", "issn": "", "pages": "2473--2482", "other_ids": {}}, "BIBREF36": {"ref_id": "b36", "title": "Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men:a randomized controlled trial", "authors": [{"first": "M", "middle": ["J"], "last": "Bolland", "suffix": ""}, {"first": "A", "middle": ["B"], "last": "Grey", "suffix": ""}, {"first": "A", "middle": ["M"], "last": "Horne", "suffix": ""}, {"first": "S", "middle": ["E"], "last": "Briggs", "suffix": ""}, {"first": "M", "middle": ["G"], "last": "Thomas", "suffix": ""}, {"first": "R", "middle": ["B"], "last": "Ellis-Pegler", "suffix": ""}, {"first": "A", "middle": ["F"], "last": "Woodhouse", "suffix": ""}, {"first": "G", "middle": ["D"], "last": "Gamble", "suffix": ""}, {"first": "I", "middle": ["R"], "last": "Reid", "suffix": ""}], "year": 2007, "venue": "J Clin Endocrinol Metab", "volume": "92", "issn": "", "pages": "1283--1288", "other_ids": {}}, "BIBREF37": {"ref_id": "b37", "title": "A doubleblinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis", "authors": [{"first": "J", "middle": [], "last": "Huang", "suffix": ""}, {"first": "L", "middle": [], "last": "Meixner", "suffix": ""}, {"first": "S", "middle": [], "last": "Fern\u00e1ndez", "suffix": ""}, {"first": "J", "middle": ["A"], "last": "Mccutchan", "suffix": ""}], "year": 2009, "venue": "AIDS", "volume": "23", "issn": "", "pages": "51--57", "other_ids": {}}, "BIBREF38": {"ref_id": "b38", "title": "Avascular necrosis of bone in patients with human immunodeficiency virus infection: report of 6 cases and review of the literature", "authors": [{"first": "P", "middle": [], "last": "Brown", "suffix": ""}, {"first": "L", "middle": [], "last": "Crane", "suffix": ""}], "year": 2001, "venue": "Clin Infect Dis", "volume": "32", "issn": "", "pages": "1221--1226", "other_ids": {}}, "BIBREF39": {"ref_id": "b39", "title": "HIV and its effects on bone: a primer for rheumatologists", "authors": [{"first": "L", "middle": [], "last": "Grdmintas", "suffix": ""}, {"first": "D", "middle": ["H"], "last": "Solomon", "suffix": ""}], "year": 2012, "venue": "Curr Opin Rheumatol", "volume": "24", "issn": "", "pages": "567--575", "other_ids": {}}, "BIBREF40": {"ref_id": "b40", "title": "Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS", "authors": [{"first": "S", "middle": [], "last": "Gallitano", "suffix": ""}, {"first": "L", "middle": [], "last": "Mcdermott", "suffix": ""}, {"first": "K", "middle": [], "last": "Brar", "suffix": ""}, {"first": "E", "middle": [], "last": "Lowenstein", "suffix": ""}], "year": 2016, "venue": "J Am Acad Dermatol", "volume": "74", "issn": "", "pages": "974--980", "other_ids": {}}, "BIBREF41": {"ref_id": "b41", "title": "The rates of serious infections in HIV-infected patients who received tumor necrosis factor (TNF)-\u03b1 inhibitor therapy for concomitant autoimmune diseases", "authors": [{"first": "S", "middle": [], "last": "Wangsiricharoen", "suffix": ""}, {"first": "C", "middle": [], "last": "Ligon", "suffix": ""}, {"first": "L", "middle": [], "last": "Gedmintas", "suffix": ""}, {"first": "A", "middle": [], "last": "Dehrab", "suffix": ""}, {"first": "L", "middle": [], "last": "Calabrese", "suffix": ""}], "year": 2017, "venue": "Arthritis Care Res", "volume": "69", "issn": "", "pages": "449--452", "other_ids": {}}, "BIBREF42": {"ref_id": "b42", "title": "Inflammatory arthritis in HIV positive patients: a practical guide", "authors": [{"first": "T", "middle": [], "last": "Adizie", "suffix": ""}, {"first": "R", "middle": ["J"], "last": "Moots", "suffix": ""}, {"first": "B", "middle": [], "last": "Hodkinson", "suffix": ""}, {"first": "N", "middle": [], "last": "French", "suffix": ""}, {"first": "A", "middle": ["O"], "last": "Adebajo", "suffix": ""}], "year": 2016, "venue": "BMC Infect Dis", "volume": "16", "issn": "", "pages": "", "other_ids": {}}, "BIBREF43": {"ref_id": "b43", "title": "Patient experiences, attitudes and expectations towards receiving information about anti-TNF medication: a quantitative study", "authors": [{"first": "J", "middle": [], "last": "Packham", "suffix": ""}, {"first": "P", "middle": [], "last": "Arkell", "suffix": ""}, {"first": "T", "middle": [], "last": "Sheeran", "suffix": ""}, {"first": "A", "middle": [], "last": "Brownfield", "suffix": ""}, {"first": "A", "middle": [], "last": "Cadwgan", "suffix": ""}, {"first": "S", "middle": [], "last": "Ryan", "suffix": ""}], "year": 2017, "venue": "Clin Rheumatol", "volume": "36", "issn": "", "pages": "2595--2600", "other_ids": {}}, "BIBREF44": {"ref_id": "b44", "title": "Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals", "authors": [{"first": "D", "middle": ["L"], "last": "Fink", "suffix": ""}, {"first": "L", "middle": [], "last": "Hedley", "suffix": ""}, {"first": "R", "middle": ["F"], "last": "Miller", "suffix": ""}], "year": 2017, "venue": "Int J STD AIDS", "volume": "28", "issn": "", "pages": "110--119", "other_ids": {}}, "BIBREF45": {"ref_id": "b45", "title": "Infection risk and safety of corticosteroid use", "authors": [{"first": "J", "middle": [], "last": "Youssef", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Novosad", "suffix": ""}, {"first": "K", "middle": ["L"], "last": "Winthrop", "suffix": ""}], "year": 2016, "venue": "Rheum Dis Clin N Am", "volume": "42", "issn": "", "pages": "157--176", "other_ids": {}}, "BIBREF46": {"ref_id": "b46", "title": "European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies", "authors": [{"first": "M", "middle": ["C"], "last": "Mosca", "suffix": ""}, {"first": "C", "middle": [], "last": "Tani", "suffix": ""}, {"first": "M", "middle": [], "last": "Aringer", "suffix": ""}, {"first": "S", "middle": [], "last": "Bombardieri", "suffix": ""}, {"first": "D", "middle": [], "last": "Boumpas", "suffix": ""}, {"first": "R", "middle": [], "last": "Brey", "suffix": ""}, {"first": "R", "middle": [], "last": "Cervera", "suffix": ""}, {"first": "Doria", "middle": ["A"], "last": "", "suffix": ""}, {"first": "Jayne", "middle": ["D"], "last": "Khamashta", "suffix": ""}, {"first": "M", "middle": ["A"], "last": "Kuhn", "suffix": ""}, {"first": "A", "middle": [], "last": "Gordon", "suffix": ""}, {"first": "C", "middle": [], "last": "Petri", "suffix": ""}, {"first": "M", "middle": [], "last": "Rekvig", "suffix": ""}, {"first": "O", "middle": ["P"], "last": "Schneider", "suffix": ""}, {"first": "M", "middle": [], "last": "Sherer", "suffix": ""}, {"first": "Y", "middle": [], "last": "Shoenfeld", "suffix": ""}, {"first": "Y", "middle": [], "last": "Smolen", "suffix": ""}, {"first": "J", "middle": ["S"], "last": "Talarico", "suffix": ""}, {"first": "R", "middle": [], "last": "Tincani", "suffix": ""}, {"first": "A", "middle": [], "last": "Van Vollenhoven", "suffix": ""}, {"first": "R", "middle": [], "last": "Ward", "suffix": ""}, {"first": "M", "middle": ["M"], "last": "Werth", "suffix": ""}, {"first": "V", "middle": ["P"], "last": "Carmona", "suffix": ""}, {"first": "L", "middle": [], "last": "", "suffix": ""}], "year": 2010, "venue": "Ann Rheum Dis", "volume": "69", "issn": "", "pages": "1269--1274", "other_ids": {}}, "BIBREF47": {"ref_id": "b47", "title": "Pneumocystis pneumonia and the rheumatologist: which patients are at risk and how can PCP be prevented?", "authors": [{"first": "R", "middle": ["M"], "last": "Wolfe", "suffix": ""}, {"first": "J", "middle": ["E"], "last": "Peacock", "suffix": ""}], "year": 2017, "venue": "Curr Rheumatol Rep", "volume": "19", "issn": "", "pages": "35--44", "other_ids": {}}, "BIBREF48": {"ref_id": "b48", "title": "American College of Rheumatology recommendations for the use of disease-modifying anti-rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis", "authors": [{"first": "J", "middle": ["A"], "last": "Singh", "suffix": ""}, {"first": "D", "middle": ["E"], "last": "Furst", "suffix": ""}, {"first": "A", "middle": [], "last": "Bharat", "suffix": ""}, {"first": "J", "middle": ["R"], "last": "Curtis", "suffix": ""}, {"first": "A", "middle": ["F"], "last": "Kavanaugh", "suffix": ""}, {"first": "J", "middle": ["M"], "last": "Kremer", "suffix": ""}, {"first": "L", "middle": ["W"], "last": "Moreland", "suffix": ""}, {"first": "J", "middle": [], "last": "O&apos;dell", "suffix": ""}, {"first": "K", "middle": ["L"], "last": "Winthrop", "suffix": ""}, {"first": "T", "middle": [], "last": "Beukelman", "suffix": ""}, {"first": "S", "middle": ["L"], "last": "Bridges", "suffix": ""}, {"first": "W", "middle": ["W"], "last": "Chatham", "suffix": ""}, {"first": "H", "middle": ["E"], "last": "Paulus", "suffix": ""}, {"first": "M", "middle": [], "last": "Suarez-Almazor", "suffix": ""}, {"first": "C", "middle": [], "last": "Bombardier", "suffix": ""}, {"first": "M", "middle": [], "last": "Dougados", "suffix": ""}, {"first": "D", "middle": [], "last": "Khanna", "suffix": ""}, {"first": "C", "middle": ["M"], "last": "King", "suffix": ""}, {"first": "A", "middle": ["L"], "last": "Leong", "suffix": ""}, {"first": "E", "middle": ["L"], "last": "Matteson", "suffix": ""}, {"first": "J", "middle": ["T"], "last": "Schousboe", "suffix": ""}, {"first": "E", "middle": [], "last": "Moynihan", "suffix": ""}, {"first": "K", "middle": ["S"], "last": "Kolba", "suffix": ""}, {"first": "A", "middle": [], "last": "Jain", "suffix": ""}, {"first": "E", "middle": ["R"], "last": "Volkmann", "suffix": ""}, {"first": "H", "middle": [], "last": "Agrawal", "suffix": ""}, {"first": "S", "middle": [], "last": "Bae", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Mudano", "suffix": ""}, {"first": "N", "middle": ["M"], "last": "Patkar", "suffix": ""}, {"first": "K", "middle": ["G"], "last": "Saag", "suffix": ""}], "year": 2008, "venue": "Arthritis Care Res", "volume": "64", "issn": "", "pages": "625--639", "other_ids": {}}, "BIBREF49": {"ref_id": "b49", "title": "Infections in the management of rheumatic diseases: an update", "authors": [{"first": "S", "middle": ["A"], "last": "Botha-Scheepers", "suffix": ""}, {"first": "B", "middle": [], "last": "Sarembock", "suffix": ""}], "year": 2015, "venue": "S Afr Med J", "volume": "105", "issn": "", "pages": "", "other_ids": {}}, "BIBREF50": {"ref_id": "b50", "title": "Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "F, Han Y (2007) Distinctive rheumatic manifestations in 98 patients with human immunodeficiency virus infection in China. J Rheumatol 34:1760-1764 39. Brand M, Woodiwiss AJ, Michel F, Nayler S, Veller MG, Norton GR (2014 Aug 29) Large vessel adventitial vasculitis characterizes patients with critical lower limb ischemia with as compared to without human immunodeficiency virus infection. PLoS One 9(8): e106205 40. Pillay B, Ramdial PK, Naidoo DP (2015) HIV-associated largevessel vasculopathy: a review of the current and emerging clinicopathological spectrum in vascular surgical practice. Cardiovasc J Afr 26:70-81 41. Ferfar Y, Savey L, Comarmond C, Sadaghianloo N, Garrido M, Domont F, Valantin MA, Pourcher-Martinez V, Cluzel P, Fouret P, Chiche L, Gaudric J, Koskas F, Cacoub P, Saadoun D (2018) Largevessel vasculitis in human immunodeficiency virus-infected patients. J Vasc Surg 67:1501-1511 42. Konstantinidou MK, Nelson M, Rosendahl U, Asimakopoulos G (2016) Giant cell aortitis in treatment-naive human immunodeficiency virus and hepatitis C coinfection. Ann R Coll Surg Engl 98:e192-e194 43. Patel N, Patel N, Khan T, Patel N, Espinoza LR (2011) HIV infection and clinical spectrum of associated vasculitides. Curr Opin Rep 13:506-512 44. Patel N, Patel N, Espinoza L (2009) HIV infection and rheumatic diseases: the changing spectrum of clinical enigma. Rheum Dis Clin N Am 35:139-161 45. Johnson RM, Bergmann KR, Manaloor JJ, Yu X, Slaven JE, Kharbanda AB (2016) Pediatric Kawasaki disease and adult human immunodeficiency virus Kawasaki-like syndrome are likely the same malady. Open Forum Infect Dis 3(3):ofw160 46. Rivas-Larrauri F, Aguilar-Zanela L, Castro-Oteo P, Rosales-Hernandez LA, Otero-Mendoza F, L\u00f3pez-Herrera G, Ordo\u00f1ez-Ortega J, Garrido-Garc\u00eda M, Yamazaki-Nakashimada MA (2019) Kawasaki disease and immunodeficiencies in children: case reports and literature review. Rheumatol Int 39:1829-1838", "latex": null, "type": "figure"}, "TABREF0": {"text": "Immune reconstitution inflammatory syndrome. Post-HAART era", "latex": null, "type": "table"}, "TABREF1": {"text": "HIV-associated rheumatic manifestations in the pre-and post-HAART era Increased/decreased: +, low; ++, moderate; +++, high; \u2212, absent; ?, unclear Naovarat et al. identified 22 patients with concomitant SLE and HIV infection in their cohort of HIV patients followed longitudinally over a 25-year period. Data is similar to that previously reported by Hax et al., although they showed that the prevalence of SLE was high in black HIV-infected women, and skin/mucosal involvement and DNA antibodies were less common in patients with concomitant HIV and SLE. Of interest, patients diagnosed with HIV infection after the advent of HAART tended to present with SLE in a shorter time than patients with HIV prior to the advent of HAART [32].", "latex": null, "type": "table"}, "TABREF2": {"text": "37]. Zhang et al. have reported a high prevalence of vasculitis when compared with other rheumatic syndromes [38]. A variety of syndromes have been reported including Takayasu arteritis, polyarteritis nodosa, Kawasaki-like syndrome, Behcet-like disease, Henoch-Schonlein purpura, digital gangrene, and central nervous system vasculitis [38-46]. In addition, serum cryoglobulins and ANCA antibodies, especially pANCA, are common, up to 40-50%, but their clinical significance is uncertain (43, 44). In the HAART era, HIVinfected patients have been shown to have decreased levels of serum cryoglobulins [44].", "latex": null, "type": "table"}, "TABREF3": {"text": "Miscellaneous. Other manifestations after introduction HAART", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Pre-HAART\n</td><td>Post-HAART\n</td></tr><tr><td>Osteonecrosis + </td><td>++\n</td></tr><tr><td>Osteopenia/osteoporosis + </td><td>++\n</td></tr></table></body></html>"}, "TABREF4": {"text": "Li YC, Yang F, Ji XY, Fang ZJ, Liu J, Wang Y (2014) False human immunodeficiency virus test results associated with rheumatoid factors in rheumatoid arthritis. Chin Med Sci J 29:103-106 29. Carugati M, Franzzeti M, Torre A, Giorgi R et al (2013) Systemic lupus erythematosus and HIV infection: a whimsical relationship. Reports of two cases and review of the literature. Clin Rheumatol 32:1399-1405 30. Mody GM, Patel N, Budhoo A, Dubula T (2014) Concomitant systemic lupus erythematosus and HIV: case series and literature review. Semin Arthritis Rheum 44:186-194 31. Hax V, ALD M, Piovesan RR, Goldani LZ, Xavier RM, Monticielo OA (2018) Human immunodeficiency virus in a cohort of systemic lupus erythematosus patients. Adv Rheumatol 58(1):12. https://doi. org/10.1186/s42358-018-0003-2 32. Naovarat BS, Reveille JD, Salazar GA, Williams FM, Nguyen BY (2020) Systemic lupus erythematosus in the setting of HIV-1 infection: a longitudinal analysis. Clin Rheumatol 39:413-418 33. Mosquera JA, Ojea R, Navarro C (2010) HIV infection associated with scleroderma: report of two new case. J Clin Pathol 63:852-853 34. Okong'o LO, Webb K, Scott C (2015) HIV associated juvenile systemic sclerosis: a case report. Semin Arthritis Rheum 44:411-416 35. Newton L, van Halsema C, Neil Snowden N (2014) HIV and rheumatology : a practical guide. Reports on the Rheumatic Disease. Arthritis Research UK 36. Ghrenassia E, Martis N, Boyer J, Burel-Vandenbos F, Mekinian A, Coppo P (2015) The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review. J Autoimmun 59:19-25 37. Otedo AE, Oyoo GO, Obondi JO, Otieno CF (2005) Vasculitis in HIV: report of eight cases. East Afr Med J 82:656-659 38. Zhang X, Li H, Li T, Zhang", "latex": null, "type": "table"}}, "back_matter": []}